JP2001509369A - ガン細胞を特異的に検出する４ｂ５と命名される抗原結合フラグメント、フラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのそれらの使用 - Google Patents

ガン細胞を特異的に検出する４ｂ５と命名される抗原結合フラグメント、フラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのそれらの使用

Info

Publication number: JP2001509369A
Authority: JP; Japan
Prior art keywords: polynucleotide; composition; antibody; cells; polypeptide
Prior art date: 1997-07-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

JP2000502064A

Other languages

English (en)

Japanese (ja)

Inventor

マイケルディー．ダン，

マンソールサレー，

マークナソフ，

Original Assignee

ノボファームバイオテックインコーポレイテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-08

Filing date

1998-07-08

Publication date

2001-07-24

1998-07-08 Application filed by ノボファームバイオテックインコーポレイテッド filed Critical ノボファームバイオテックインコーポレイテッド

2001-07-24 Publication of JP2001509369A publication Critical patent/JP2001509369A/ja

Status Withdrawn legal-status Critical Current

Links

206010028980 Neoplasm Diseases 0.000 title claims abstract description 179
239000000427 antigen Substances 0.000 title claims abstract description 84
108091007433 antigens Proteins 0.000 title claims abstract description 83
102000036639 antigens Human genes 0.000 title claims abstract description 83
230000027455 binding Effects 0.000 title claims abstract description 73
239000012634 fragment Substances 0.000 title claims abstract description 60
125000003729 nucleotide group Chemical group 0.000 title claims description 49
239000002773 nucleotide Substances 0.000 title claims description 46
201000011510 cancer Diseases 0.000 title abstract description 87
238000001514 detection method Methods 0.000 title description 15
230000002265 prevention Effects 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 201
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 191
229920001184 polypeptide Polymers 0.000 claims abstract description 186
102000040430 polynucleotide Human genes 0.000 claims abstract description 183
108091033319 polynucleotide Proteins 0.000 claims abstract description 183
239000002157 polynucleotide Substances 0.000 claims abstract description 183
238000000034 method Methods 0.000 claims abstract description 96
239000000203 mixture Substances 0.000 claims abstract description 58
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
239000002246 antineoplastic agent Substances 0.000 claims abstract description 6
230000009826 neoplastic cell growth Effects 0.000 claims abstract description 6
210000004027 cell Anatomy 0.000 claims description 181
239000000523 sample Substances 0.000 claims description 52
230000028993 immune response Effects 0.000 claims description 39
108060003951 Immunoglobulin Proteins 0.000 claims description 29
102000018358 immunoglobulin Human genes 0.000 claims description 29
230000001900 immune effect Effects 0.000 claims description 27
239000002671 adjuvant Substances 0.000 claims description 23
125000003275 alpha amino acid group Chemical group 0.000 claims description 23
239000013604 expression vector Substances 0.000 claims description 18
230000002163 immunogen Effects 0.000 claims description 17
239000012472 biological sample Substances 0.000 claims description 15
230000000295 complement effect Effects 0.000 claims description 15
239000007787 solid Substances 0.000 claims description 15
239000003814 drug Substances 0.000 claims description 14
108091026890 Coding region Proteins 0.000 claims description 12
150000001875 compounds Chemical class 0.000 claims description 12
229960005486 vaccine Drugs 0.000 claims description 12
102000004190 Enzymes Human genes 0.000 claims description 11
108090000790 Enzymes Proteins 0.000 claims description 11
229940079593 drug Drugs 0.000 claims description 11
230000004927 fusion Effects 0.000 claims description 11
239000000546 pharmaceutical excipient Substances 0.000 claims description 11
229920000642 polymer Polymers 0.000 claims description 11
230000009257 reactivity Effects 0.000 claims description 11
206010046865 Vaccinia virus infection Diseases 0.000 claims description 10
125000000539 amino acid group Chemical group 0.000 claims description 10
238000002360 preparation method Methods 0.000 claims description 10
208000007089 vaccinia Diseases 0.000 claims description 10
230000001225 therapeutic effect Effects 0.000 claims description 9
102000004127 Cytokines Human genes 0.000 claims description 8
108090000695 Cytokines Proteins 0.000 claims description 8
108010076504 Protein Sorting Signals Proteins 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 8
102000000588 Interleukin-2 Human genes 0.000 claims description 7
108010002350 Interleukin-2 Proteins 0.000 claims description 7
230000001580 bacterial effect Effects 0.000 claims description 7
239000000872 buffer Substances 0.000 claims description 7
239000003053 toxin Substances 0.000 claims description 7
231100000765 toxin Toxicity 0.000 claims description 7
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 6
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 6
230000015572 biosynthetic process Effects 0.000 claims description 6
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
230000008512 biological response Effects 0.000 claims description 4
239000013599 cloning vector Substances 0.000 claims description 4
238000007918 intramuscular administration Methods 0.000 claims description 4
239000002502 liposome Substances 0.000 claims description 4
238000007920 subcutaneous administration Methods 0.000 claims description 4
239000000758 substrate Substances 0.000 claims description 4
108090001008 Avidin Proteins 0.000 claims description 3
102000004388 Interleukin-4 Human genes 0.000 claims description 3
108090000978 Interleukin-4 Proteins 0.000 claims description 3
229960002685 biotin Drugs 0.000 claims description 3
235000020958 biotin Nutrition 0.000 claims description 3
239000011616 biotin Substances 0.000 claims description 3
239000007850 fluorescent dye Substances 0.000 claims description 3
239000003112 inhibitor Substances 0.000 claims description 3
229910052751 metal Inorganic materials 0.000 claims description 3
239000002184 metal Substances 0.000 claims description 3
230000005298 paramagnetic effect Effects 0.000 claims description 3
102000003390 tumor necrosis factor Human genes 0.000 claims description 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
229940028885 interleukin-4 Drugs 0.000 claims description 2
238000007912 intraperitoneal administration Methods 0.000 claims description 2
230000001737 promoting effect Effects 0.000 claims description 2
231100000617 superantigen Toxicity 0.000 claims description 2
239000003607 modifier Substances 0.000 claims 2
102000014150 Interferons Human genes 0.000 claims 1
108010050904 Interferons Proteins 0.000 claims 1
102000013462 Interleukin-12 Human genes 0.000 claims 1
108010065805 Interleukin-12 Proteins 0.000 claims 1
102000004856 Lectins Human genes 0.000 claims 1
108090001090 Lectins Proteins 0.000 claims 1
101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 claims 1
239000002955 immunomodulating agent Substances 0.000 claims 1
230000002584 immunomodulator Effects 0.000 claims 1
229940121354 immunomodulator Drugs 0.000 claims 1
229940047124 interferons Drugs 0.000 claims 1
229940117681 interleukin-12 Drugs 0.000 claims 1
238000007913 intrathecal administration Methods 0.000 claims 1
238000010253 intravenous injection Methods 0.000 claims 1
239000002523 lectin Substances 0.000 claims 1
230000000116 mitigating effect Effects 0.000 claims 1
238000007911 parenteral administration Methods 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 38
201000010099 disease Diseases 0.000 abstract description 27
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 27
201000001441 melanoma Diseases 0.000 abstract description 13
206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 9
108020001507 fusion proteins Proteins 0.000 abstract description 9
102000037865 fusion proteins Human genes 0.000 abstract description 9
206010029260 Neuroblastoma Diseases 0.000 abstract description 5
230000001613 neoplastic effect Effects 0.000 abstract description 5
206010018338 Glioma Diseases 0.000 abstract description 4
208000032612 Glial tumor Diseases 0.000 abstract description 3
206010039491 Sarcoma Diseases 0.000 abstract description 3
208000021712 Soft tissue sarcoma Diseases 0.000 abstract description 2
201000005296 lung carcinoma Diseases 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 description 59
235000001014 amino acid Nutrition 0.000 description 49
229940024606 amino acid Drugs 0.000 description 46
238000003556 assay Methods 0.000 description 44
238000012360 testing method Methods 0.000 description 44
150000001413 amino acids Chemical class 0.000 description 43
102000004169 proteins and genes Human genes 0.000 description 36
235000018102 proteins Nutrition 0.000 description 35
239000013598 vector Substances 0.000 description 34
230000000694 effects Effects 0.000 description 31
239000003153 chemical reaction reagent Substances 0.000 description 29
239000013612 plasmid Substances 0.000 description 27
210000001519 tissue Anatomy 0.000 description 23
210000001744 T-lymphocyte Anatomy 0.000 description 22
238000004519 manufacturing process Methods 0.000 description 19
230000004083 survival effect Effects 0.000 description 19
241000699666 Mus <mouse, genus> Species 0.000 description 18
210000004408 hybridoma Anatomy 0.000 description 18
239000000126 substance Substances 0.000 description 15
239000012636 effector Substances 0.000 description 14
206010006187 Breast cancer Diseases 0.000 description 13
208000026310 Breast neoplasm Diseases 0.000 description 13
238000010367 cloning Methods 0.000 description 13
-1 rRNA Proteins 0.000 description 13
210000002966 serum Anatomy 0.000 description 13
239000007790 solid phase Substances 0.000 description 13
230000006870 function Effects 0.000 description 12
230000001965 increasing effect Effects 0.000 description 12
230000004044 response Effects 0.000 description 12
238000006467 substitution reaction Methods 0.000 description 12
238000005406 washing Methods 0.000 description 12
108020004414 DNA Proteins 0.000 description 11
230000003302 anti-idiotype Effects 0.000 description 11
230000005847 immunogenicity Effects 0.000 description 11
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 11
241000282412 Homo Species 0.000 description 10
229940088598 enzyme Drugs 0.000 description 10
238000002372 labelling Methods 0.000 description 10
125000005647 linker group Chemical group 0.000 description 10
208000020816 lung neoplasm Diseases 0.000 description 10
230000004048 modification Effects 0.000 description 10
238000012986 modification Methods 0.000 description 10
206010009944 Colon cancer Diseases 0.000 description 9
230000034994 death Effects 0.000 description 9
231100000517 death Toxicity 0.000 description 9
238000009396 hybridization Methods 0.000 description 9
235000000346 sugar Nutrition 0.000 description 9
241000700605 Viruses Species 0.000 description 8
238000011534 incubation Methods 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
201000005202 lung cancer Diseases 0.000 description 8
210000004881 tumor cell Anatomy 0.000 description 8
102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 7
238000002965 ELISA Methods 0.000 description 7
206010027476 Metastases Diseases 0.000 description 7
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
238000001415 gene therapy Methods 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
239000007788 liquid Substances 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
238000013518 transcription Methods 0.000 description 7
230000035897 transcription Effects 0.000 description 7
230000014616 translation Effects 0.000 description 7
208000001333 Colorectal Neoplasms Diseases 0.000 description 6
241000196324 Embryophyta Species 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 6
241000238631 Hexapoda Species 0.000 description 6
230000000890 antigenic effect Effects 0.000 description 6
210000003719 b-lymphocyte Anatomy 0.000 description 6
230000008859 change Effects 0.000 description 6
238000002512 chemotherapy Methods 0.000 description 6
230000003013 cytotoxicity Effects 0.000 description 6
231100000135 cytotoxicity Toxicity 0.000 description 6
238000003745 diagnosis Methods 0.000 description 6
238000003384 imaging method Methods 0.000 description 6
238000003018 immunoassay Methods 0.000 description 6
230000001976 improved effect Effects 0.000 description 6
210000004072 lung Anatomy 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
239000002609 medium Substances 0.000 description 6
238000000746 purification Methods 0.000 description 6
238000010561 standard procedure Methods 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
201000009030 Carcinoma Diseases 0.000 description 5
241000699670 Mus sp. Species 0.000 description 5
229920002684 Sepharose Polymers 0.000 description 5
230000024932 T cell mediated immunity Effects 0.000 description 5
241000700618 Vaccinia virus Species 0.000 description 5
210000000481 breast Anatomy 0.000 description 5
239000000969 carrier Substances 0.000 description 5
210000001072 colon Anatomy 0.000 description 5
208000029742 colonic neoplasm Diseases 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
230000007423 decrease Effects 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
210000003527 eukaryotic cell Anatomy 0.000 description 5
230000012010 growth Effects 0.000 description 5
238000010438 heat treatment Methods 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
230000003993 interaction Effects 0.000 description 5
230000000670 limiting effect Effects 0.000 description 5
239000012528 membrane Substances 0.000 description 5
238000002156 mixing Methods 0.000 description 5
238000001959 radiotherapy Methods 0.000 description 5
230000009467 reduction Effects 0.000 description 5
238000002271 resection Methods 0.000 description 5
238000000926 separation method Methods 0.000 description 5
241000894007 species Species 0.000 description 5
238000001356 surgical procedure Methods 0.000 description 5
108700012359 toxins Proteins 0.000 description 5
238000001890 transfection Methods 0.000 description 5
101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
108010074328 Interferon-gamma Proteins 0.000 description 4
239000004472 Lysine Substances 0.000 description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
108091028043 Nucleic acid sequence Proteins 0.000 description 4
102000006601 Thymidine Kinase Human genes 0.000 description 4
108020004440 Thymidine kinase Proteins 0.000 description 4
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
238000007792 addition Methods 0.000 description 4
229940037003 alum Drugs 0.000 description 4
239000011324 bead Substances 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
238000012875 competitive assay Methods 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
230000021615 conjugation Effects 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
230000003053 immunization Effects 0.000 description 4
238000002649 immunization Methods 0.000 description 4
239000002596 immunotoxin Substances 0.000 description 4
238000011065 in-situ storage Methods 0.000 description 4
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 4
230000003211 malignant effect Effects 0.000 description 4
239000003550 marker Substances 0.000 description 4
230000009401 metastasis Effects 0.000 description 4
239000013642 negative control Substances 0.000 description 4
238000001556 precipitation Methods 0.000 description 4
238000003127 radioimmunoassay Methods 0.000 description 4
230000006798 recombination Effects 0.000 description 4
238000005215 recombination Methods 0.000 description 4
230000010076 replication Effects 0.000 description 4
238000012552 review Methods 0.000 description 4
238000010186 staining Methods 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
238000013519 translation Methods 0.000 description 4
241000894006 Bacteria Species 0.000 description 3
241000701022 Cytomegalovirus Species 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
102100037850 Interferon gamma Human genes 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
208000015634 Rectal Neoplasms Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
101710120037 Toxin CcdB Proteins 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000003321 amplification Effects 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000003915 cell function Effects 0.000 description 3
230000036755 cellular response Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000002591 computed tomography Methods 0.000 description 3
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
238000001641 gel filtration chromatography Methods 0.000 description 3
238000010353 genetic engineering Methods 0.000 description 3
210000002443 helper t lymphocyte Anatomy 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
229940072221 immunoglobulins Drugs 0.000 description 3
238000001114 immunoprecipitation Methods 0.000 description 3
238000009169 immunotherapy Methods 0.000 description 3
230000002637 immunotoxin Effects 0.000 description 3
231100000608 immunotoxin Toxicity 0.000 description 3
229940051026 immunotoxin Drugs 0.000 description 3
210000001165 lymph node Anatomy 0.000 description 3
229920002521 macromolecule Polymers 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
230000001394 metastastic effect Effects 0.000 description 3
206010061289 metastatic neoplasm Diseases 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
238000004806 packaging method and process Methods 0.000 description 3
239000002245 particle Substances 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
102000013415 peroxidase activity proteins Human genes 0.000 description 3
108040007629 peroxidase activity proteins Proteins 0.000 description 3
230000008569 process Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
208000000587 small cell lung carcinoma Diseases 0.000 description 3
239000000243 solution Substances 0.000 description 3
150000008163 sugars Chemical class 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
238000011277 treatment modality Methods 0.000 description 3
238000011269 treatment regimen Methods 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
238000001262 western blot Methods 0.000 description 3
210000005253 yeast cell Anatomy 0.000 description 3
HPZMWTNATZPBIH-UHFFFAOYSA-N 1-methyladenine Chemical compound CN1C=NC2=NC=NC2=C1N HPZMWTNATZPBIH-UHFFFAOYSA-N 0.000 description 2
RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
108010032595 Antibody Binding Sites Proteins 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
206010003445 Ascites Diseases 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 2
108010075254 C-Peptide Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
241000700199 Cavia porcellus Species 0.000 description 2
108091035707 Consensus sequence Proteins 0.000 description 2
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
101150083678 IL2 gene Proteins 0.000 description 2
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
108010074338 Lymphokines Proteins 0.000 description 2
102000008072 Lymphokines Human genes 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
108010058846 Ovalbumin Proteins 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108010020346 Polyglutamic Acid Proteins 0.000 description 2
108010039918 Polylysine Proteins 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
108010039491 Ricin Proteins 0.000 description 2
241000607142 Salmonella Species 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
108010071390 Serum Albumin Proteins 0.000 description 2
102000007562 Serum Albumin Human genes 0.000 description 2
206010041067 Small cell lung cancer Diseases 0.000 description 2
230000005867 T cell response Effects 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
108010034949 Thyroglobulin Proteins 0.000 description 2
102000009843 Thyroglobulin Human genes 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000002730 additional effect Effects 0.000 description 2
208000009956 adenocarcinoma Diseases 0.000 description 2
239000003463 adsorbent Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
210000003679 cervix uteri Anatomy 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
230000009918 complex formation Effects 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 2
238000013461 design Methods 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
238000010586 diagram Methods 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
229960002949 fluorouracil Drugs 0.000 description 2
238000002825 functional assay Methods 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
230000008348 humoral response Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
239000000367 immunologic factor Substances 0.000 description 2
230000003308 immunostimulating effect Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
239000012678 infectious agent Substances 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
230000009545 invasion Effects 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
238000007726 management method Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
102000006240 membrane receptors Human genes 0.000 description 2
108020004084 membrane receptors Proteins 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
208000021039 metastatic melanoma Diseases 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
229940126619 mouse monoclonal antibody Drugs 0.000 description 2
125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 2
230000035772 mutation Effects 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
229940043515 other immunoglobulins in atc Drugs 0.000 description 2
229940092253 ovalbumin Drugs 0.000 description 2
238000002559 palpation Methods 0.000 description 2
244000052769 pathogen Species 0.000 description 2
230000007170 pathology Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
229920002643 polyglutamic acid Polymers 0.000 description 2
229920000656 polylysine Polymers 0.000 description 2
238000006116 polymerization reaction Methods 0.000 description 2
239000013641 positive control Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000002243 precursor Substances 0.000 description 2
208000029340 primitive neuroectodermal tumor Diseases 0.000 description 2
XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
238000004393 prognosis Methods 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
150000003230 pyrimidines Chemical class 0.000 description 2
238000011002 quantification Methods 0.000 description 2
230000005855 radiation Effects 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
230000008707 rearrangement Effects 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
206010038038 rectal cancer Diseases 0.000 description 2
201000001275 rectum cancer Diseases 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
206010041823 squamous cell carcinoma Diseases 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
229960000814 tetanus toxoid Drugs 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
229960002175 thyroglobulin Drugs 0.000 description 2
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
229940035893 uracil Drugs 0.000 description 2
239000004474 valine Substances 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
238000009736 wetting Methods 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
DFUSDJMZWQVQSF-XLGIIRLISA-N (2r)-2-methyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical class OC1=CC=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 DFUSDJMZWQVQSF-XLGIIRLISA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
SATCOUWSAZBIJO-UHFFFAOYSA-N 1-methyladenine Natural products N=C1N(C)C=NC2=C1NC=N2 SATCOUWSAZBIJO-UHFFFAOYSA-N 0.000 description 1
WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
SVBOROZXXYRWJL-UHFFFAOYSA-N 2-[(4-oxo-2-sulfanylidene-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=S)NC1=O SVBOROZXXYRWJL-UHFFFAOYSA-N 0.000 description 1
HCYQTNUNMRYQLZ-UHFFFAOYSA-N 2-[(6-methyl-2,4-dioxo-1H-pyrimidin-5-yl)amino]acetic acid Chemical compound C(=O)(O)CNC=1C(NC(NC=1C)=O)=O HCYQTNUNMRYQLZ-UHFFFAOYSA-N 0.000 description 1
XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
101710088758 23kDa protein Proteins 0.000 description 1
WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
NIOWRPKKLZMTPC-UHFFFAOYSA-N 5-pent-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CCCC#CC1=CNC(=O)NC1=O NIOWRPKKLZMTPC-UHFFFAOYSA-N 0.000 description 1
KABRXLINDSPGDF-UHFFFAOYSA-N 7-bromoisoquinoline Chemical compound C1=CN=CC2=CC(Br)=CC=C21 KABRXLINDSPGDF-UHFFFAOYSA-N 0.000 description 1
MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
108020005176 AU Rich Elements Proteins 0.000 description 1
208000035657 Abasia Diseases 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
206010004593 Bile duct cancer Diseases 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
241000251204 Chimaeridae Species 0.000 description 1
JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108090000317 Chymotrypsin Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
108700010070 Codon Usage Proteins 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
108010047041 Complementarity Determining Regions Proteins 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
HAIWUXASLYEWLM-UHFFFAOYSA-N D-manno-Heptulose Natural products OCC1OC(O)(CO)C(O)C(O)C1O HAIWUXASLYEWLM-UHFFFAOYSA-N 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
229920002271 DEAE-Sepharose Polymers 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
238000012270 DNA recombination Methods 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
206010014967 Ependymoma Diseases 0.000 description 1
102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
108010088842 Fibrinolysin Proteins 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
102000002464 Galactosidases Human genes 0.000 description 1
108010093031 Galactosidases Proteins 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
206010018378 Glomerulonephritis rapidly progressive Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
101000636168 Grapevine leafroll-associated virus 3 (isolate United States/NY1) Movement protein p5 Proteins 0.000 description 1
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101000957351 Homo sapiens Myc-associated zinc finger protein Proteins 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
HSNZZMHEPUFJNZ-UHFFFAOYSA-N L-galacto-2-Heptulose Natural products OCC(O)C(O)C(O)C(O)C(=O)CO HSNZZMHEPUFJNZ-UHFFFAOYSA-N 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
208000018142 Leiomyosarcoma Diseases 0.000 description 1
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
206010027457 Metastases to liver Diseases 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
206010027940 Mood altered Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
102100038750 Myc-associated zinc finger protein Human genes 0.000 description 1
241000186359 Mycobacterium Species 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
241001644525 Nastus productus Species 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 description 1
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
244000061176 Nicotiana tabacum Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
102000019040 Nuclear Antigens Human genes 0.000 description 1
108010051791 Nuclear Antigens Proteins 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
108020004711 Nucleic Acid Probes Proteins 0.000 description 1
201000010133 Oligodendroglioma Diseases 0.000 description 1
208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
101150102573 PCR1 gene Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
102000015439 Phospholipases Human genes 0.000 description 1
108010064785 Phospholipases Proteins 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
208000007452 Plasmacytoma Diseases 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 1
241000405965 Scomberomorus brasiliensis Species 0.000 description 1
HAIWUXASLYEWLM-AZEWMMITSA-N Sedoheptulose Natural products OC[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@](O)(CO)O1 HAIWUXASLYEWLM-AZEWMMITSA-N 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
108090000787 Subtilisin Proteins 0.000 description 1
208000004732 Systemic Vasculitis Diseases 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
206010062122 Testicular choriocarcinoma Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
241001230284 Theclini Species 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
108091036066 Three prime untranslated region Proteins 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
206010070863 Toxicity to various agents Diseases 0.000 description 1
101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
208000008383 Wilms tumor Diseases 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
125000002015 acyclic group Chemical group 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000012387 aerosolization Methods 0.000 description 1
238000011256 aggressive treatment Methods 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229940059260 amidate Drugs 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000006023 anti-tumor response Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
210000003567 ascitic fluid Anatomy 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
MMIMIFULGMZVPO-UHFFFAOYSA-N benzyl 3-bromo-2,6-dinitro-5-phenylmethoxybenzoate Chemical compound [O-][N+](=O)C1=C(C(=O)OCC=2C=CC=CC=2)C([N+](=O)[O-])=C(Br)C=C1OCC1=CC=CC=C1 MMIMIFULGMZVPO-UHFFFAOYSA-N 0.000 description 1
102000015736 beta 2-Microglobulin Human genes 0.000 description 1
108010081355 beta 2-Microglobulin Proteins 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
201000007180 bile duct carcinoma Diseases 0.000 description 1
238000005842 biochemical reaction Methods 0.000 description 1
239000003124 biologic agent Substances 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
201000006598 bladder squamous cell carcinoma Diseases 0.000 description 1
229960004395 bleomycin sulfate Drugs 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
208000030270 breast disease Diseases 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
201000006662 cervical adenocarcinoma Diseases 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
208000011654 childhood malignant neoplasm Diseases 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
208000014911 choriocarcinoma of testis Diseases 0.000 description 1
201000000336 choriocarcinoma of the testis Diseases 0.000 description 1
239000012916 chromogenic reagent Substances 0.000 description 1
208000024207 chronic leukemia Diseases 0.000 description 1
229960002376 chymotrypsin Drugs 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000003501 co-culture Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000002967 competitive immunoassay Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
201000005637 crescentic glomerulonephritis Diseases 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
238000004163 cytometry Methods 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Natural products NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
229960003901 dacarbazine Drugs 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
210000001787 dendrite Anatomy 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
238000012631 diagnostic technique Methods 0.000 description 1
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
229960005156 digoxin Drugs 0.000 description 1
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
238000013399 early diagnosis Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000008393 encapsulating agent Substances 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
235000021550 forms of sugar Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
150000002243 furanoses Chemical class 0.000 description 1
229940044627 gamma-interferon Drugs 0.000 description 1
150000002270 gangliosides Chemical class 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
102000005396 glutamine synthetase Human genes 0.000 description 1
108020002326 glutamine synthetase Proteins 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
239000000710 homodimer Substances 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000005745 host immune response Effects 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
239000000677 immunologic agent Substances 0.000 description 1
229940124541 immunological agent Drugs 0.000 description 1
239000012133 immunoprecipitate Substances 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
239000000411 inducer Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
201000010985 invasive ductal carcinoma Diseases 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
230000001788 irregular Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
230000029226 lipidation Effects 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
239000008263 liquid aerosol Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
238000002761 liquid phase assay Methods 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
244000144972 livestock Species 0.000 description 1
229960002247 lomustine Drugs 0.000 description 1
201000005249 lung adenocarcinoma Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
230000005291 magnetic effect Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
229960000350 mitotane Drugs 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
238000009448 modified atmosphere packaging Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
235000019837 monoammonium phosphate Nutrition 0.000 description 1
239000000178 monomer Substances 0.000 description 1
229940035032 monophosphoryl lipid a Drugs 0.000 description 1
230000007510 mood change Effects 0.000 description 1
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
239000002636 mycotoxin Substances 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000002956 necrotizing effect Effects 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
238000004848 nephelometry Methods 0.000 description 1
201000008026 nephroblastoma Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910001453 nickel ion Inorganic materials 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002853 nucleic acid probe Substances 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
208000030355 pancreatic large cell neuroendocrine carcinoma Diseases 0.000 description 1
208000030312 pancreatic small cell neuroendocrine carcinoma Diseases 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
229960002340 pentostatin Drugs 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
238000009521 phase II clinical trial Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
229960000952 pipobroman Drugs 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
229940012957 plasmin Drugs 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
108700028325 pokeweed antiviral Proteins 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
229920002627 poly(phosphazenes) Polymers 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
229960001586 procarbazine hydrochloride Drugs 0.000 description 1
238000012545 processing Methods 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
201000005825 prostate adenocarcinoma Diseases 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
150000003214 pyranose derivatives Chemical class 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
238000012797 qualification Methods 0.000 description 1
238000010791 quenching Methods 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
238000011363 radioimmunotherapy Methods 0.000 description 1
238000011552 rat model Methods 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
238000012827 research and development Methods 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
108091008020 response regulators Proteins 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
229940102127 rubidium chloride Drugs 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
HSNZZMHEPUFJNZ-SHUUEZRQSA-N sedoheptulose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO HSNZZMHEPUFJNZ-SHUUEZRQSA-N 0.000 description 1
239000013605 shuttle vector Substances 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
208000000649 small cell carcinoma Diseases 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
229940031439 squalene Drugs 0.000 description 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000003860 storage Methods 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
230000036561 sun exposure Effects 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000001502 supplementing effect Effects 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
229940002004 the magic bullet Drugs 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
229960003087 tioguanine Drugs 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
229960001322 trypsin Drugs 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
238000004879 turbidimetry Methods 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
229960001055 uracil mustard Drugs 0.000 description 1
229940124856 vaccine component Drugs 0.000 description 1
229960004982 vinblastine sulfate Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
229960002110 vincristine sulfate Drugs 0.000 description 1
229960005212 vindesine sulfate Drugs 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
238000012800 visualization Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Life Sciences & Earth Sciences (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

JP2000502064A 1997-07-08 1998-07-08 ガン細胞を特異的に検出する４ｂ５と命名される抗原結合フラグメント、フラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのそれらの使用 Withdrawn JP2001509369A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US5194597P	1997-07-08	1997-07-08
US60/051,945		1997-07-08
PCT/IB1998/001046 WO1999002545A2 (fr)	1997-07-08	1998-07-08	Fragments de liaison antigeniques designes par 4b5, qui detectent specifiquement les cellules cancereuses, nucleotides codant lesdits fragments et leur utilisation pour la prophylaxie et la detection des cancers

Publications (1)

Publication Number	Publication Date
JP2001509369A true JP2001509369A (ja)	2001-07-24

Family

ID=21974384

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2000502064A Withdrawn JP2001509369A (ja)	1997-07-08	1998-07-08	ガン細胞を特異的に検出する４ｂ５と命名される抗原結合フラグメント、フラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのそれらの使用

Country Status (6)

Country	Link
EP (1)	EP1000082A2 (fr)
JP (1)	JP2001509369A (fr)
AU (1)	AU7927398A (fr)
CA (1)	CA2295375A1 (fr)
NZ (1)	NZ501990A (fr)
WO (1)	WO1999002545A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2010510504A (ja) *	2006-11-21	2010-04-02	エフ．ホフマン−ラロシュアーゲー	免疫測定法における標準としての抗イディオタイプ結合体およびその使用

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE309360T1 (de)	1994-03-08	2005-11-15	Human Genome Sciences Inc	Vaskularer endothelialer wachstumsfaktor 2
US7153827B1 (en)	1994-03-08	2006-12-26	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2 and methods of use
US7186688B1 (en)	1994-03-08	2007-03-06	Human Genome Sciences, Inc.	Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6040157A (en)	1994-03-08	2000-03-21	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US7109308B1 (en)	1994-03-08	2006-09-19	Human Genome Sciences, Inc.	Antibodies to human vascular endothelial growth factor 2
US5932540A (en)	1994-03-08	1999-08-03	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US6608182B1 (en)	1994-03-08	2003-08-19	Human Genome Sciences, Inc.	Human vascular endothelial growth factor 2
US7223724B1 (en)	1999-02-08	2007-05-29	Human Genome Sciences, Inc.	Use of vascular endothelial growth factor to treat photoreceptor cells
JP2003527116A (ja) *	2000-03-15	2003-09-16	インサイト・ゲノミックス・インコーポレイテッド	ヒト免疫応答タンパク質
NZ518077A (en)	2000-08-04	2003-11-28	Human Genome Sciences Inc	Biologically active fragments, analogues and derivatives of VEGF-2 for the treatment of peripheral artery diseases such as critical limb ischemia and coronary disease
DE10059930A1 (de) *	2000-11-23	2002-05-29	Fischer Peter	Mittel humanen Ursprungs zur Vakzination gegen GD2-pos. Tumore
WO2002083704A1 (fr)	2001-04-13	2002-10-24	Human Genome Sciences, Inc.	Facteur de croissance 2, endothelial, vasculaire
US7402312B2 (en)	2001-04-13	2008-07-22	Human Genome Sciences, Inc.	Antibodies to vascular endothelial growth factor 2 (VEGF-2)
EP1380290A1 (fr) *	2002-07-09	2004-01-14	Universitair Medisch Centrum Utrecht	La voie de la structure cross-béta et sa pertinence thérapeutique
US7473424B2 (en) *	2003-01-31	2009-01-06	The Scripps Research Institute	Anti-dengue virus antibodies and compositions
WO2015095002A1 (fr) *	2013-12-16	2015-06-25	Texas Tech University System	Anticorps monoclonaux anti-ron en tant que système d'administration de médicaments cytotoxiques pour une thérapie anticancéreuse ciblée

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5653977A (en) *	1993-09-09	1997-08-05	Uab Research Foundation	Anti-idiotypic antibody that mimics the GD2 antigen
DK0796280T3 (da) *	1994-12-28	2003-04-22	Univ Kentucky	Murint monoklonalt anti-idiotypisk antistof 3H1
US5612030A (en) *	1995-01-17	1997-03-18	University Of Kentucky Research Foundation	Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma

1998
- 1998-07-08 CA CA002295375A patent/CA2295375A1/fr not_active Abandoned
- 1998-07-08 WO PCT/IB1998/001046 patent/WO1999002545A2/fr not_active Application Discontinuation
- 1998-07-08 JP JP2000502064A patent/JP2001509369A/ja not_active Withdrawn
- 1998-07-08 EP EP98929569A patent/EP1000082A2/fr not_active Withdrawn
- 1998-07-08 AU AU79273/98A patent/AU7927398A/en not_active Abandoned
- 1998-07-08 NZ NZ501990A patent/NZ501990A/xx unknown

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2010510504A (ja) *	2006-11-21	2010-04-02	エフ．ホフマン−ラロシュアーゲー	免疫測定法における標準としての抗イディオタイプ結合体およびその使用

Also Published As

Publication number	Publication date
WO1999002545A2 (fr)	1999-01-21
EP1000082A2 (fr)	2000-05-17
WO1999002545A3 (fr)	1999-04-01
NZ501990A (en)	2002-09-27
CA2295375A1 (fr)	1999-01-21
AU7927398A (en)	1999-02-08

Legal Events

Date

Code

Title

Description

2005-10-04

A300

Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20051004

Publication	Publication Date	Title
JP4124486B2 (ja)	2008-07-23	ガン細胞を特異的に検出する抗原結合フラグメント、このフラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのその使用
JP5039027B2 (ja)	2012-10-03	結腸癌および膵臓癌のための、組換え型モノクローナル抗体および対応する抗原
JP5601836B2 (ja)	2014-10-08	Ｔｅｓ７およびｔｅｓ７に結合する抗体
JP5185815B2 (ja)	2013-04-17	抗ｃｄ７１モノクローナル抗体および悪性腫瘍細胞を治療するためのその使用
JP2000511421A5 (fr)	2007-12-06
RU2488593C2 (ru)	2013-07-27	Человеческое опухолеспецифическое моноклональное антитело
JP2001509369A (ja)	2001-07-24	ガン細胞を特異的に検出する４ｂ５と命名される抗原結合フラグメント、フラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのそれらの使用
US7183384B2 (en)	2007-02-27	Monoclonal antibody 7H11 reactive with human cancer
BRPI0621800B1 (pt)	2020-03-24	Anticorpos que se ligam à proteína FZD10, clones de hibridoma, composições farmacêuticas, kit compreendendo os referidos anticorpos, e método para diagnose ou prognose de uma doença que é associada a homólogo FZD10 ou de uma predisposição para desenvolver a doença em um indivíduo
US20010047083A1 (en)	2001-11-29	Murine anti-idiotype antibody 3H1
ES2747920T3 (es)	2020-03-12	Anticuerpo anti-NKP46 para diagnóstico de un linfoma de células T periféricas no cutáneo (PTCL)
JP2008508904A (ja)	2008-03-27	トランスフェリンレセプター抗体
JP2002508651A (ja)	2002-03-19	モノクローナル抗体１ａ７ならびにメラノーマおよび小細胞ガンの処置のための使用
KR20070102555A (ko)	2007-10-18	Ａｄａｍ-9 조절자
US20030118593A1 (en)	2003-06-26	Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
WO2019045086A1 (fr)	2019-03-07	UTILISATION D'UN ANTICORPS SPÉCIFIQUE POUR TGF-β1 ACTIF OU LATENT
WO2006123829A1 (fr)	2006-11-23	ANTICORPS DIRIGE CONTRE PAP2a ET SON UTILISATION DANS DES BUTS DE DIAGNOSTIC ET THERAPEUTIQUES
JP2009536217A (ja)	2009-10-08	Ｂ細胞障害の治療における免疫グロブリン結合細胞表面決定基
JP7019609B2 (ja)	2022-02-15	卵巣がんおよび膵臓がんのためのバイオマーカーとしてムチン様タンパク質（ｍｌｐ）を検出するためのモノクローナル抗体、組成物および方法
Itoh et al.	2009	Antibody epitope peptides as potential inducers of IgG antibodies against CD98 oncoprotein
CA2255540C (fr)	2007-05-15	Fragments de liaison a l'antigene detectant specifiquement des cellules cancereuses, nucleotides codant lesdits fragments, et leur utilisation pour la prophylaxie et le depistage de cancers
US7115722B1 (en)	2006-10-03	Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
JP2008056647A (ja)	2008-03-13	Ｆｃα／μレセプターに対する抗体
JP2000511764A (ja)	2000-09-12	マウスモノクローナル抗イディオタイプ抗体１１ｄ１０およびその使用方法
AU7243200A (en)	2001-03-22	Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers

JP2001509369A - ガン細胞を特異的に検出する４ｂ５と命名される抗原結合フラグメント、フラグメントをコードするヌクレオチド、ならびにガンの予防および検出のためのそれらの使用 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (1)

Family

ID=21974384

Family Applications (1)

Country Status (6)

Cited By (1)

Families Citing this family (16)

Family Cites Families (3)

Cited By (1)

Also Published As

Similar Documents

Legal Events